Literature DB >> 22482803

Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy.

Isabella Scionti1, Francesca Greco, Giulia Ricci, Monica Govi, Patricia Arashiro, Liliana Vercelli, Angela Berardinelli, Corrado Angelini, Giovanni Antonini, Michelangelo Cao, Antonio Di Muzio, Maurizio Moggio, Lucia Morandi, Enzo Ricci, Carmelo Rodolico, Lucia Ruggiero, Lucio Santoro, Gabriele Siciliano, Giuliano Tomelleri, Carlo Pietro Trevisan, Giuliana Galluzzi, Woodring Wright, Mayana Zatz, Rossella Tupler.   

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is a common hereditary myopathy causally linked to reduced numbers (≤8) of 3.3 kilobase D4Z4 tandem repeats at 4q35. However, because individuals carrying D4Z4-reduced alleles and no FSHD and patients with FSHD and no short allele have been observed, additional markers have been proposed to support an FSHD molecular diagnosis. In particular a reduction in the number of D4Z4 elements combined with the 4A(159/161/168)PAS haplotype (which provides the possibility of expressing DUX4) is currently used as the genetic signature uniquely associated with FSHD. Here, we analyzed these DNA elements in more than 800 Italian and Brazilian samples of normal individuals unrelated to any FSHD patients. We find that 3% of healthy subjects carry alleles with a reduced number (4-8) of D4Z4 repeats on chromosome 4q and that one-third of these alleles, 1.3%, occur in combination with the 4A161PAS haplotype. We also systematically characterized the 4q35 haplotype in 253 unrelated FSHD patients. We find that only 127 of them (50.1%) carry alleles with 1-8 D4Z4 repeats associated with 4A161PAS, whereas the remaining FSHD probands carry different haplotypes or alleles with a greater number of D4Z4 repeats. The present study shows that the current genetic signature of FSHD is a common polymorphism and that only half of FSHD probands carry this molecular signature. Our results suggest that the genetic basis of FSHD, which is remarkably heterogeneous, should be revisited, because this has important implications for genetic counseling and prenatal diagnosis of at-risk families.
Copyright © 2012 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22482803      PMCID: PMC3322229          DOI: 10.1016/j.ajhg.2012.02.019

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  44 in total

1.  Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD).

Authors:  M M O Tonini; M R Passos-Bueno; A Cerqueira; S R Matioli; R Pavanello; M Zatz
Journal:  Neuromuscul Disord       Date:  2004-01       Impact factor: 4.296

2.  Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy.

Authors:  C Wijmenga; J E Hewitt; L A Sandkuijl; L N Clark; T J Wright; H G Dauwerse; A M Gruter; M H Hofker; P Moerer; R Williamson
Journal:  Nat Genet       Date:  1992-09       Impact factor: 38.330

3.  Contractions of D4Z4 on 4qB subtelomeres do not cause facioscapulohumeral muscular dystrophy.

Authors:  Richard J F L Lemmers; Mariëlle Wohlgemuth; Rune R Frants; George W Padberg; Eva Morava; Silvere M van der Maarel
Journal:  Am J Hum Genet       Date:  2004-10-04       Impact factor: 11.025

4.  Linkage analyses of five chromosome 4 markers localizes the facioscapulohumeral muscular dystrophy (FSHD) gene to distal 4q35.

Authors:  B Weiffenbach; R Bagley; K Falls; C Hyser; D Storvick; S J Jacobsen; P Schultz; J Mendell; K Willems van Dijk; E C Milner
Journal:  Am J Hum Genet       Date:  1992-08       Impact factor: 11.025

5.  Diagnostic criteria for facioscapulohumeral muscular dystrophy.

Authors:  G W Padberg; P W Lunt; M Koch; M Fardeau
Journal:  Neuromuscul Disord       Date:  1991       Impact factor: 4.296

6.  FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit.

Authors:  J C van Deutekom; C Wijmenga; E A van Tienhoven; A M Gruter; J E Hewitt; G W Padberg; G J van Ommen; M H Hofker; R R Frants
Journal:  Hum Mol Genet       Date:  1993-12       Impact factor: 6.150

7.  Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy.

Authors:  J E Hewitt; R Lyle; L N Clark; E M Valleley; T J Wright; C Wijmenga; J C van Deutekom; F Francis; P T Sharpe; M Hofker
Journal:  Hum Mol Genet       Date:  1994-08       Impact factor: 6.150

8.  Genetic counselling in facioscapulohumeral muscular dystrophy.

Authors:  P W Lunt; P S Harper
Journal:  J Med Genet       Date:  1991-10       Impact factor: 6.318

9.  Monozygotic twins with facioscapulohumeral dystrophy (FSHD): implications for genotype/phenotype correlation. FSH-DY Group.

Authors:  R C Griggs; R Tawil; M McDermott; J Forrester; D Figlewicz; B Weiffenbach
Journal:  Muscle Nerve Suppl       Date:  1995

10.  X-linked and FSH dystrophies in one family.

Authors:  B R Lecky; J M MacKenzie; A P Read; D E Wilcox
Journal:  Neuromuscul Disord       Date:  1991       Impact factor: 4.296

View more
  53 in total

1.  The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1.

Authors:  Sabrina Sacconi; Richard J L F Lemmers; Judit Balog; Patrick J van der Vliet; Pauline Lahaut; Merlijn P van Nieuwenhuizen; Kirsten R Straasheijm; Rashmie D Debipersad; Marianne Vos-Versteeg; Leonardo Salviati; Alberto Casarin; Elena Pegoraro; Rabi Tawil; Egbert Bakker; Stephen J Tapscott; Claude Desnuelle; Silvère M van der Maarel
Journal:  Am J Hum Genet       Date:  2013-09-26       Impact factor: 11.025

2.  Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2.

Authors:  Richard J L F Lemmers; Jelle J Goeman; Patrick J van der Vliet; Merlijn P van Nieuwenhuizen; Judit Balog; Marianne Vos-Versteeg; Pilar Camano; Maria Antonia Ramos Arroyo; Ivonne Jerico; Mark T Rogers; Daniel G Miller; Meena Upadhyaya; Jan J G M Verschuuren; Adolfo Lopez de Munain Arregui; Baziel G M van Engelen; George W Padberg; Sabrina Sacconi; Rabi Tawil; Stephen J Tapscott; Bert Bakker; Silvère M van der Maarel
Journal:  Hum Mol Genet       Date:  2014-09-25       Impact factor: 6.150

3.  FSHD1 and FSHD2 form a disease continuum.

Authors:  Sabrina Sacconi; Audrey Briand-Suleau; Marilyn Gros; Christian Baudoin; Richard J L F Lemmers; Sophie Rondeau; Nadira Lagha; Pilvi Nigumann; Chiara Cambieri; Angela Puma; Françoise Chapon; Tanya Stojkovic; Christophe Vial; Françoise Bouhour; Michelangelo Cao; Elena Pegoraro; Philippe Petiot; Anthony Behin; Bras Marc; Bruno Eymard; Andoni Echaniz-Laguna; Pascal Laforet; Leonardo Salviati; Marc Jeanpierre; Gaël Cristofari; Silvère M van der Maarel
Journal:  Neurology       Date:  2019-04-12       Impact factor: 9.910

4.  Tissue-specific activities of the Fat1 cadherin cooperate to control neuromuscular morphogenesis.

Authors:  Françoise Helmbacher
Journal:  PLoS Biol       Date:  2018-05-16       Impact factor: 8.029

Review 5.  Genetic and epigenetic contributors to FSHD.

Authors:  Lucia Daxinger; Stephen J Tapscott; Silvère M van der Maarel
Journal:  Curr Opin Genet Dev       Date:  2015-09-07       Impact factor: 5.578

Review 6.  Facioscapulohumeral muscular dystrophy: consequences of chromatin relaxation.

Authors:  Silvère M van der Maarel; Daniel G Miller; Rabi Tawil; Galina N Filippova; Stephen J Tapscott
Journal:  Curr Opin Neurol       Date:  2012-10       Impact factor: 5.710

7.  A distal auxiliary element facilitates cleavage and polyadenylation of Dux4 mRNA in the pathogenic haplotype of FSHD.

Authors:  Natoya Peart; Eric J Wagner
Journal:  Hum Genet       Date:  2017-05-24       Impact factor: 4.132

Review 8.  Emerging preclinical animal models for FSHD.

Authors:  Angela Lek; Fedik Rahimov; Peter L Jones; Louis M Kunkel
Journal:  Trends Mol Med       Date:  2015-03-20       Impact factor: 11.951

Review 9.  Genotype-phenotype correlations in FSHD.

Authors:  Nikolay Zernov; Mikhail Skoblov
Journal:  BMC Med Genomics       Date:  2019-03-13       Impact factor: 3.063

10.  Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine.

Authors:  Rabi Tawil; John T Kissel; Chad Heatwole; Shree Pandya; Gary Gronseth; Michael Benatar
Journal:  Neurology       Date:  2015-07-28       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.